Prosensa’s Duchenne muscular dystrophy treatment endured a Phase III setback that led partner GlaxoSmithKline to head for the exit, but the Dutch biotech is back with a new analysis of drisapersen’s data that could spell a path forward, sending its shares up 25%.

…read more

Source: Prosensa heralds new hope for once-failed muscular dystrophy drug


0 No comments